Japan Keytruda NSCLC Approval Sets Stage For Opdivo Showdown
Executive Summary
Keytruda has been approved in Japan for lung cancer, including first-line use, in a batch of new regulatory clearances that also include the country's first prescription drug for irritable bowel syndrome with constipation.
You may also be interested in...
Japan Slashes Opdivo Price 50% After Prescriptions Surge
Merck’s Keytruda could see its launch price set lower too after Opdivo’s rapidly rising use in lung cancer triggers maximum statutory price cut.
Ono Files Japan Patent Action As Keytruda Nears Market
Hot on the heels of Keytruda's US approval for first-line use in lung cancer, and just ahead of the drug’s first local launch, rival PD-1 player Ono has launched a patent infringement suit in Japan against Merck, adding to similar actions brought elsewhere by its global Opdivo partner BMS.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.